MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published In The Journal Of Clinical Endocrinology And Metabolism
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published In The Journal Of Clinical Endocrinology And Metabolism
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the Company's parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP). The publication, titled "MBX 2109, a Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-in-Human, Randomized Trial", was published in The Journal of Clinical Endocrinology and Metabolism (JCEM) and can be accessed here.
MBX Biosciences, Inc.（納斯達克股票代碼：MBX）是一家臨床階段的生物製藥公司，專注於發現和開發用於治療內分泌和代謝失調的新型精準肽療法。該公司正在開發的用於治療低下垂的甲狀旁腺激素（PTH）肽前體藥物MBX 2109的1期研究結果甲狀旁腺功能亢進 (HP)。該出版物名爲 「MBX 2109，每週一次的甲狀旁腺激素替代療法前藥：第一階段，首次人體隨機試驗」，發表在《臨床內分泌與代謝雜誌》（JCEM）上，可在此處訪問。
